FGFR2 and intrahepatic cholangiocarcinoma: These findings emphasize the potential clinical utility of targeted therapies that inhibit FGFR signaling pathways in ICC, but also underscore the importance of selecting the appropriate SMKI based on the specific FGFR2 mutation present.